| SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE |
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE
| |
|
|
|
|
As
of
September 30,
2021 |
|
|
As
of
December 31,
2020 |
|
| |
|
Life |
|
|
Carrying |
|
|
Carrying |
|
| |
|
(Years) |
|
|
Amount |
|
|
Amount |
|
| |
|
|
|
|
(unaudited) |
|
|
|
|
| Asuragen acquisition: |
|
|
|
|
|
|
|
|
|
|
|
|
| Thyroid |
|
|
9 |
|
|
$ |
8,519 |
|
|
$ |
8,519 |
|
| RedPath acquisition: |
|
|
|
|
|
|
|
|
|
|
|
|
| Pancreas
test |
|
|
7 |
|
|
|
16,141 |
|
|
|
16,141 |
|
| Barrett’s
test |
|
|
9 |
|
|
|
6,682 |
|
|
|
6,682 |
|
| BioPharma acquisition: |
|
|
|
|
|
|
|
|
|
|
|
|
| Trademarks |
|
|
10 |
|
|
|
1,600 |
|
|
|
1,600 |
|
| Customer
relationships |
|
|
8 |
|
|
|
5,700 |
|
|
|
5,700 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| CLIA Lab |
|
|
2.3 |
|
|
|
609 |
|
|
|
609 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Total |
|
|
|
|
|
$ |
39,251 |
|
|
$ |
39,251 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated Amortization |
|
|
|
|
|
$ |
(31,237 |
) |
|
$ |
(27,900 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Net Carrying Value |
|
|
|
|
|
$ |
8,014 |
|
|
$ |
11,351 |
|
|
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE
| |
|
|
|
|
As
of
December 31, 2020 |
|
|
As
of
December 31, 2019 |
|
| |
|
Life |
|
|
Carrying |
|
|
Carrying |
|
| |
|
(Years) |
|
|
Amount |
|
|
Amount |
|
| |
|
|
|
|
|
|
|
|
|
| Asuragen
acquisition: |
|
|
|
|
|
|
|
|
|
|
|
|
| Thyroid |
|
|
9 |
|
|
$ |
8,519 |
|
|
$ |
8,519 |
|
| RedPath
acquisition: |
|
|
|
|
|
|
|
|
|
|
|
|
| Pancreas
test |
|
|
7 |
|
|
|
16,141 |
|
|
|
16,141 |
|
| Barrett’s
test |
|
|
9 |
|
|
|
6,682 |
|
|
|
6,719 |
|
| BioPharma
acquisition: |
|
|
|
|
|
|
|
|
|
|
|
|
| Trademarks |
|
|
10 |
|
|
|
1,600 |
|
|
|
1,600 |
|
| Customer
relationships |
|
|
8 |
|
|
|
5,700 |
|
|
|
5,700 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| CLIA
Lab |
|
|
2.3 |
|
|
$ |
609 |
|
|
$ |
609 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Total |
|
|
|
|
|
$ |
39,251 |
|
|
$ |
39,288 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated
Amortization |
|
|
|
|
|
$ |
(27,900 |
) |
|
$ |
(23,439 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Net
Carrying Value |
|
|
|
|
|
$ |
11,351 |
|
|
$ |
15,849 |
|
|
| Schedule of Future Estimated Amortization Expense |
SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE
| 2021 |
|
|
2022 |
|
|
2023 |
|
|
2024 |
|
|
2025 |
|
| $ |
1,112 |
|
|
$ |
2,155 |
|
|
$ |
2,099 |
|
|
$ |
873 |
|
|
$ |
873 |
|
|
Schedule of Future Estimated Amortization Expense
| 2021 |
|
|
2022 |
|
|
2023 |
|
|
2024 |
|
|
2025 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| $ |
4,078 |
|
|
$ |
2,156 |
|
|
$ |
1,745 |
|
|
$ |
873 |
|
|
$ |
873 |
|
|
| SCHEDULE OF GOODWILL CARRYING VALUE |
The
following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to September 30, 2021:
SCHEDULE OF GOODWILL CARRYING VALUE
| |
|
Carrying |
|
| |
|
Amount |
|
| Balance as of December 31, 2020 |
|
$ |
8,433 |
|
| Adjustments |
|
|
- |
|
| Balance as of September
30, 2021 |
|
$ |
8,433 |
|
|
The
following table displays a roll forward of the carrying amount of goodwill from January 1, 2019 to December 31, 2020:
SCHEDULE OF GOODWILL CARRYING VALUE
| |
|
Carrying |
|
| |
|
Amount |
|
| Balance as of January 1, 2019 |
|
$ |
- |
|
| Goodwill
acquired |
|
|
8,273 |
|
| Adjustments |
|
|
160 |
|
| Balance as of December 31, 2019 |
|
|
8,433 |
|
| Adjustments |
|
|
- |
|
| Balance as of December 31, 2020 |
|
$ |
8,433 |
|
|